On May 30th local time, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved an extended indication for its CAR-T therapy, Breyanzi (lisocabtagene maraleucel; liso cel), for adult patients with recurrent or refractory mantle cell lymphoma (MCL) who have previously received at least 2 lines of systemic therapy, including those who have previously received treatment with Bruton tyrosine kinase (BTK) inhibitors. The press release states that Breyanzi is currently the only CAR-T therapy approved by the US FDA for the treatment of four different subtypes of non Hodgkin's lymphoma, enabling it to treat patients with B-cell malignancy.